Dimitry Nuyten, Arcus CMO
December 19, 2022 05:01 PM ESTUpdated 05:25 PM
Bioregnum
R&D

Gilead and Ar­cus want you to be­lieve again in TIG­IT. But mixed ARC-7 da­ta are rolling out to a tough crowd

Roche let the air out of the TIG­IT par­ty bal­loon with a pair of crush­ing Phase III fail­ures. Now Gilead $GILD and Ar­cus $RCUS are …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times